Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya

被引：14

作者：

Inzaule, Seth C. ^{[1
,2
,3
]}

Hamers, Raph L. ^{[1
,2
,4
]}

Mukui, Irene ^{[5
]}

Were, Kennedy ^{[3
]}

Owiti, Prestone ^{[3
]}

Kwaro, Daniel ^{[3
]}

de Wit, Tobias F. Rinke ^{[1
,2
]}

Zeh, Clement ^{[6
]}

机构：

[1] Acad Med Ctr, Dept Global Hlth, Amsterdam, Netherlands

[2] Amsterdam Inst Global Hlth & Dev, Pietersbergweg 17, NL-1105 BM Amsterdam, Netherlands

[3] Kenya Govt Med Res Ctr, Kisumu, Kenya

[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, Dept Internal Med, Amsterdam, Netherlands

[5] Natl AIDS & STI Control Programme, Nairobi, Kenya

[6] US Ctr Dis Control & Prevent, Kisumu, Kenya

来源：

AIDS | 2017年 / 31卷 / 10期

关键词：

ANTIRETROVIRAL DRUG-RESISTANCE; ADULTS;

D O I：

10.1097/QAD.0000000000001500

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harbouring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first and second-line drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs.

引用

页码：1495 / 1498

页数：4

共 50 条

[11] Ibalizumab for the treatment of multidrug-resistant HIV-1 infection
Rizza, S. A.
Bhatia, R.
Zeuli, J.
Temesgen, Z.
DRUGS OF TODAY, 2019, 55 (01) : 25 - 34
[12] Primary infection with a multidrug-resistant HIV-1 strain
Morelon, S
Harzic, M
Chadenat, ML
Dupont, C
Rouveix, E
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (18) : 2259 - 2260
[13] Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
Blair, Hannah A.
DRUGS, 2020, 80 (02) : 189 - 196
[14] Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
Hannah A. Blair
Drugs, 2020, 80 : 189 - 196
[15] Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Kozal, Michael
Aberg, Judith
Pialoux, Gilles
Cahn, Pedro
Thompson, Melanie
Molina, Jean-Michel
Grinsztejn, Beatriz
Diaz, Ricardo
Castagna, Antonella
Kumar, Princy
Latiff, Gulam
DeJesus, Edwin
Gummel, Mark
Gartland, Margaret
Pierce, Amy
Ackerman, Peter
Llamoso, Cyril
Lataillade, Max
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (13): : 1232 - 1243
[16] Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus
Lee, Natalie E. E.
Sutherland, Rebecca K. K.
CURRENT OPINION IN INFECTIOUS DISEASES, 2023, 36 (01) : 15 - 19
[17] Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India
Kumar, Agibothu Kupparam Hemanth
Kumar, Alok
Kannan, Thiruvengadam
Bhatia, Rakesh
Agarwal, Dipti
Kumar, Santosh
Dayal, Rajeshwar
Singh, Sheo Pratap
Ramachandran, Geetha
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
[18] Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates
Prammananan, T
Arjratanakool, W
Chailprasert, A
Tingtoy, N
Leechawengwong, M
Asawapokee, N
Leelarasamee, A
Dhiraputra, C
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2005, 9 (02) : 216 - 219
[19] Hypothyroidism during second-line treatment of multidrug-resistant tuberculosis: a prospective study
Bares, R.
Khalid, N.
Daniel, H.
Dittmann, H.
Reimold, M.
Gallwitz, B.
Schmotzer, C.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (07) : 876 - 881
[20] Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection
Hiryak, Kayla
Koren, David E.
ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) : 792 - 797

← 1 2 3 4 5 →